Compare LYG & PFE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LYG | PFE |
|---|---|---|
| Founded | 1695 | 1849 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.5B | 147.6B |
| IPO Year | 2012 | 2013 |
| Metric | LYG | PFE |
|---|---|---|
| Price | $6.21 | $26.79 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 14 |
| Target Price | N/A | ★ $29.29 |
| AVG Volume (30 Days) | 15.1M | ★ 32.6M |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | 3.73% | ★ 6.55% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.43 |
| Revenue | N/A | ★ $62,579,000,000.00 |
| Revenue This Year | $13.36 | N/A |
| Revenue Next Year | $7.28 | N/A |
| P/E Ratio | ★ $62.13 | $62.31 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.20 | $23.59 |
| 52 Week High | $6.34 | $28.75 |
| Indicator | LYG | PFE |
|---|---|---|
| Relative Strength Index (RSI) | 56.56 | 65.68 |
| Support Level | $5.84 | $26.42 |
| Resistance Level | $6.33 | $27.75 |
| Average True Range (ATR) | 0.09 | 0.54 |
| MACD | -0.01 | 0.16 |
| Stochastic Oscillator | 77.66 | 86.98 |
Lloyds is a retail and commercial bank headquartered in the United Kingdom. The bank operates via three business segments: retail, commercial banking, and insurance and wealth. In retail, Lloyds offers primarily mortgages (66% of its loan portfolio), credit cards, and current accounts to its customers. Its commercial banking operation provides lending, transaction banking, working capital management, and debt capital market services to large companies and financial institutions in the UK. Insurance and wealth round out the product lineup with life and property insurance as well as pension solutions and high-net-worth asset management services.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.